[go: up one dir, main page]

AR059686A1 - Piperazinas terapeuticas - Google Patents

Piperazinas terapeuticas

Info

Publication number
AR059686A1
AR059686A1 ARP070100831A ARP070100831A AR059686A1 AR 059686 A1 AR059686 A1 AR 059686A1 AR P070100831 A ARP070100831 A AR P070100831A AR P070100831 A ARP070100831 A AR P070100831A AR 059686 A1 AR059686 A1 AR 059686A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
alkoxy
aryl
halo
Prior art date
Application number
ARP070100831A
Other languages
English (en)
Inventor
Terence P Keenan
Alan P Kaplan
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of AR059686A1 publication Critical patent/AR059686A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de piperazina, composiciones que comprenden tales compuestos, y métodos de preparacion del compuesto. Los compuestos son inhibidores e la funcion PDE4 y son utiles para mejorar la funcion cognitiva, retardo mental, trastornos psicoticos y neuroticos y tumor cerebral. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula 1: en donde: R1 es H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8- alquilo C1-6, halo(C1-6)alquilo, arilo, aril(C1-6)alquilo, aril(C1-6)alcoxi, aril(C1-6)alcanoilo, het, het(C1-6)alquilo, het(C1-6)alcoxi, o het(C1-6)alcanoilo; n es 1 o 2; m es 1 o 2; W es O, S, o dos hidrogenos; X es O o N-Y-R4, Y es un enlace directo, -CH2-, -C(=O)-, -C(=S)-, -O-, -C(=O)O-, - OC(=O)-, -C(=O)Nra-, -S-, -S(=O), -S(=O)2, o -S(=O)2Nra-; R4 es H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, hidroxi, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, hidroxi(C1- 6)alquilo, alcoxicarbonilo C1-6, carboxi, arilo, aril(C1-6)alquilo, het, NRdRe, C(=O)NRdRe, NRdRe(C1-6)alquilo, o het(C1-6)alquilo; Ra es H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C2-6, o cicloalquil C3-8-alquilo C1-6; Z es un anillo fenilo sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquilo C1-6, halo(C1-6)alquilo, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, alcoxi C1-6, halo(C1-6)alcoxi, cicloalquiloxi C3-8, y cicloalquil C3-8-alcoxi C1-6; o Z es un anillo fenilo que está fusionado con un sistema de anillo mono o bicíclico saturado, parcialmente insaturado o aromático que comprende entre aproximadamente 3 y aproximadamente 8 átomos seleccionados entre carbono, oxígeno, y NRb, en donde el sistema de anillo mono o bicíclico de Z está opcionalmente sustituido con uno o más Rc, y en donde el anillo fenilo que está fusionado con el sistema de anillo mono o bicíclico está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquiloC1-6, halo (C1-6)alquilo, cicloalquilo C3-8, cicloalquil 3-8-alquilo C1-6, alcoxi C1-6, halo(C2-6)alcoxi, cicloalquiloxi C3-8, cicloalquil C3-8-alcoxi C1-6; Rb está ausente , H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C2-6, o cicloalquil C3-8-alquilo C1-6; Rc es alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, arilo, aril(C1-6)alquilo, aril(C1-6)alcoxi, aril(C1-6)alcanoilo, het, het(C1-6)alquilo, het(C1-6)alcoxi, o het(C1-6)alcanoilo; cada Rd y Re es en forma independiente H, hidroxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6,alqueniloxi C2-6, alquiniloxi C2-6, alcanoilo C1-6, alcoxicarbonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, arilo, aril (C1-6)alquilo, NRfRg, o aril(C1-6)alcoxi; y cada Rf y Rg es en forma independiente H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, arilo, aril(C1-6)alquilo, o aril(C1-6)alcoxi; o Rf y Rg junto con el nitrogeno al cual están unidos forman un anillo pirrolidino, piperidino, piperazino, morfolino, o tiomorfolino; en donde cualquier grupo arilo o het de R1 o R4 está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquilo C1-6, fenilo, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, cicloalquiloxi C3-8, cicloalquil C3-8-alcoxi C1-6, halo(C2-6)alcoxi, ciano, nitro, halo, carboxi o NRdRe; y en donde el anillo con un contenido de X está opcionalmente sustituido sobre carbon con uno o más halo, alquilo C1-6, o alcoxi C1-6, o una sal aceptable para uso farmacéutico del mismo.
ARP070100831A 2006-02-28 2007-02-28 Piperazinas terapeuticas AR059686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77729106P 2006-02-28 2006-02-28

Publications (1)

Publication Number Publication Date
AR059686A1 true AR059686A1 (es) 2008-04-23

Family

ID=38279005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100831A AR059686A1 (es) 2006-02-28 2007-02-28 Piperazinas terapeuticas

Country Status (14)

Country Link
US (4) US7829713B2 (es)
EP (2) EP1989188B1 (es)
JP (1) JP2009528363A (es)
CN (1) CN101490017B (es)
AR (1) AR059686A1 (es)
AU (1) AU2007221021B2 (es)
BR (1) BRPI0708337A2 (es)
CA (1) CA2644069A1 (es)
ES (1) ES2462240T3 (es)
IL (1) IL193674A0 (es)
NZ (1) NZ570844A (es)
SG (2) SG171635A1 (es)
TW (1) TW200804309A (es)
WO (1) WO2007100852A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
JP2010521444A (ja) * 2007-03-12 2010-06-24 バイオリポックス エービー 炎症の治療において有用なピペリジノン類
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
ES2533990T3 (es) * 2010-02-24 2015-04-16 Research Triangle Institute Antagonistas de receptores opioides de arilpiperazina
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
KR101589837B1 (ko) 2011-06-22 2016-01-29 퍼듀 퍼머 엘피 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
CA3128846C (en) 2012-07-27 2025-05-06 Sato Pharmaceutical Co. Ltd. COMPOSITE OF DIFLUOROMETHYLENE
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
JP2016505001A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CN105143207B (zh) 2013-03-14 2018-04-24 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
AU2020373047A1 (en) 2019-10-31 2022-05-19 ESCAPE Bio, Inc. Solid forms of an S1P-receptor modulator

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996507A (en) * 1959-09-09 1961-08-15 Abbott Lab Piperazine compounds
US3306903A (en) * 1965-10-07 1967-02-28 Council Scient Ind Res 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates
FR2262964B1 (es) * 1973-04-05 1978-07-28 Synthelabo
AT330777B (de) * 1973-09-08 1976-07-26 Thomae Gmbh Dr K Verfahren zur herstellung von neuen isochinolinderivaten und deren salzen
DE2345422C2 (de) * 1973-09-08 1983-12-22 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte Isochinolyl-arylpiperazine diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung
GB1575904A (en) * 1976-04-23 1980-10-01 Lilly Industries Ltd Phenyl piperazines
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4666911A (en) * 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
FR2533212A1 (fr) * 1982-09-22 1984-03-23 Lipha Benzo-et thieno-triazine-1,2,3 ones-4 procedes de preparation et medicaments les contenant
FR2551753B2 (fr) * 1982-09-22 1986-02-28 Lipha Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant
DE3442860A1 (de) * 1984-11-24 1986-05-28 Kali-Chemie Pharma Gmbh, 3000 Hannover 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3- on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3586794T2 (de) * 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
US4845100A (en) 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4960776A (en) * 1987-01-28 1990-10-02 A. H. Robins Company, Inc. 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and heterocyclicamino)alkyl)-1-piperazinecarboxamides
US5204482A (en) * 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
US5086055A (en) * 1990-12-24 1992-02-04 A. H. Robins Company, Incorporated Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions
TW197429B (es) * 1991-05-01 1993-01-01 Dtsuka Seiyaku Kk
FR2680172B1 (fr) 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
DE4241563A1 (de) * 1992-12-10 1994-06-16 Basf Ag Neue Triazolochinazoline, ihre Herstellung und Verwendung
JPH10152470A (ja) * 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
BR9813926A (pt) 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
WO2001068600A2 (en) * 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Limited Benzylated pde4 inhibitors
US8153646B2 (en) * 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP1389189A2 (en) * 2001-05-22 2004-02-18 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
MXPA05001334A (es) 2002-08-02 2005-09-08 Argenta Discovery Ltd Acidos tienil-hidroxamicos sustituidos como inhibidores de la desacetilasa de histona.
CN1688580A (zh) 2002-08-08 2005-10-26 记忆药物公司 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物
WO2004024728A2 (en) * 2002-09-16 2004-03-25 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
AU2005325271A1 (en) * 2004-05-06 2006-07-27 Plexxikon, Inc. PDE4B inhibitors and uses therefor
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
BRPI0517263A (pt) 2004-10-29 2008-10-07 Astrazeneca Ab novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
GT200600042A (es) * 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
EP1931658A2 (en) 2005-09-07 2008-06-18 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
DE502006004066D1 (de) * 2006-04-19 2009-08-06 Boehringer Ingelheim Pharma Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP2222638A2 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation

Also Published As

Publication number Publication date
US8501745B2 (en) 2013-08-06
TW200804309A (en) 2008-01-16
CN101490017B (zh) 2013-01-23
CN101490017A (zh) 2009-07-22
US8338405B2 (en) 2012-12-25
ES2462240T3 (es) 2014-05-22
CA2644069A1 (en) 2007-09-07
SG171634A1 (en) 2011-06-29
HK1185063A1 (en) 2014-02-07
US7829713B2 (en) 2010-11-09
WO2007100852A1 (en) 2007-09-07
IL193674A0 (en) 2009-05-04
AU2007221021B2 (en) 2013-01-17
US20110065689A1 (en) 2011-03-17
US20110065688A1 (en) 2011-03-17
EP2562168A1 (en) 2013-02-27
US20070203124A1 (en) 2007-08-30
NZ570844A (en) 2011-11-25
BRPI0708337A2 (pt) 2011-05-24
EP2562168B1 (en) 2014-04-16
US20140038945A1 (en) 2014-02-06
EP1989188A1 (en) 2008-11-12
AU2007221021A1 (en) 2007-09-07
EP1989188B1 (en) 2015-07-22
SG171635A1 (en) 2011-06-29
JP2009528363A (ja) 2009-08-06

Similar Documents

Publication Publication Date Title
AR059686A1 (es) Piperazinas terapeuticas
ES2575914T3 (es) Derivados condensados de aminodihidrotiazina como inhibidores de BACE
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
AR066502A1 (es) Compuestos amino- heterociclicos
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
AR088663A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina agonistas de receptores canabinoides
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
CR8349A (es) Derivados de dihidrobenzofuranilo alcanamina y metodos para su uso
JP2017222709A5 (es)
AR088970A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina
AR057984A1 (es) DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE
AR034264A1 (es) Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas
CO2018008799A2 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
NZ610018A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR076688A1 (es) Derivados de isoquinolin-1(2h)-ona
AR076401A1 (es) Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
AR067648A1 (es) Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR065333A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
AR058728A1 (es) Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina, metodo de preparacion,medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
AR046603A1 (es) Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc

Legal Events

Date Code Title Description
FB Suspension of granting procedure